Eli Lilly-Backed Aktis Oncology Gets $317.7 Million in US IPO

Aktis Oncology Inc., a clinical-stage biotechnology company that counts Eli Lilly & Co. among its backers, raised $317.7 million in an initial public offering priced at the top of the marketed range.